首页 > 最新文献

Current HIV Research最新文献

英文 中文
Prevalence of Metabolic Syndrome in Iranian Adults Receiving Antiretroviral Treatment for HIV. 接受抗逆转录病毒治疗的伊朗成人中代谢综合征的患病率
IF 1 4区 医学 Q4 IMMUNOLOGY Pub Date : 2025-01-01 DOI: 10.2174/011570162X340090250204072449
Hamid Khazdooz, Ladan Abbasian, Nooshin Shirzad, Pouria Khashayar, SeyedAhmad SeyedAlinaghi, Mahsa Malekahmadi, Mahboobeh Hemmatabadi

Background: The increased risk ofmetabolic syndrome (MetS) and its subcomponents among people living with HIV/AIDS, especially in developing countries, is well documented with the global pooled prevalence of the related risk factors in this population.

Objective: This study aimed to explore the prevalence of MetS among Iranian People living with HIV according to the ATP III and Iranian criteria.

Methods: The cross-sectional study was conducted on consecutive patients who visited THE referral centre for AIDS/HIV between May to December 2023. A total of 130 participants (n=83; 63.8%male) were investigated based on the inclusion criteria, which included having a minimum age of 25 and a maximum of 65 years and following a stable ART treatment regimen for at least six months. A Chi-square test was used to determine the relationship between the categorical variables. Uni/Multi-variable linear regression analysis was used to quantify the associations between MetS and HIV by the independent variables.

Results: The incidence of MetS according to ATP III and Iranian criteria were 42 (32.3%) and 45 (34.6%), which was higher in older patients (p=0.001) and those with more duration since HIV diagnosis (p=0.02). Around 33.1% and 16.1% were overweight and obese, respectively. Among the components of MetS, the highest prevalence (50.8%) was related to low HDL, and the lowest was related to fasting blood sugar (21.5%). The average body fat mass, protein mass, Soft lean mass, and percentage body fat were 18.54 ± 9.46 kg, 10.91 ± 2.17 kg, 51.31 ± 9.61 kg, and 24.86±10.25% that were higher in MetS group (p<0.05).

Conclusion: Our study points out the high prevalence of MetS in an Iranian population living with HIV, especially those suffering from the underlying disease for a longer time. Conducting multi-centric studies with larger sample sizes is needed to confirm our results and determine the most effective measures.

背景:在艾滋病毒/艾滋病感染者中,特别是在发展中国家,代谢综合征(MetS)及其亚成分的风险增加,这一现象在全球范围内的相关危险因素的普遍存在中得到了充分的记录。目的:本研究旨在根据ATP III和伊朗标准探讨伊朗HIV感染者中MetS的流行情况。方法:对2023年5月至12月在The AIDS/HIV转诊中心连续就诊的患者进行横断面研究。共130名参与者(n=83;63.8%男性)根据纳入标准进行调查,纳入标准包括最低年龄为25岁,最高年龄为65岁,接受稳定的ART治疗方案至少6个月。采用卡方检验确定分类变量之间的关系。采用单变量/多变量线性回归分析,通过自变量量化MetS与HIV之间的相关性。结果:根据ATP III和伊朗标准,MetS的发生率分别为42(32.3%)和45(34.6%),其中老年患者(p=0.001)和HIV诊断后持续时间较长的患者(p=0.02)较高。超重和肥胖的比例分别为33.1%和16.1%。在MetS的组成部分中,发病率最高(50.8%)与低HDL有关,最低与空腹血糖有关(21.5%)。平均体脂质量、蛋白质质量、软瘦质量和体脂百分比分别为18.54±9.46 kg、10.91±2.17 kg、51.31±9.61 kg和24.86±10.25%,met组较高(p结论:本研究指出伊朗HIV感染者中MetS的患病率较高,特别是那些长期患有基础疾病的人群。需要进行更大样本量的多中心研究来确认我们的结果并确定最有效的措施。
{"title":"Prevalence of Metabolic Syndrome in Iranian Adults Receiving Antiretroviral Treatment for HIV.","authors":"Hamid Khazdooz, Ladan Abbasian, Nooshin Shirzad, Pouria Khashayar, SeyedAhmad SeyedAlinaghi, Mahsa Malekahmadi, Mahboobeh Hemmatabadi","doi":"10.2174/011570162X340090250204072449","DOIUrl":"10.2174/011570162X340090250204072449","url":null,"abstract":"<p><strong>Background: </strong>The increased risk ofmetabolic syndrome (MetS) and its subcomponents among people living with HIV/AIDS, especially in developing countries, is well documented with the global pooled prevalence of the related risk factors in this population.</p><p><strong>Objective: </strong>This study aimed to explore the prevalence of MetS among Iranian People living with HIV according to the ATP III and Iranian criteria.</p><p><strong>Methods: </strong>The cross-sectional study was conducted on consecutive patients who visited THE referral centre for AIDS/HIV between May to December 2023. A total of 130 participants (n=83; 63.8%male) were investigated based on the inclusion criteria, which included having a minimum age of 25 and a maximum of 65 years and following a stable ART treatment regimen for at least six months. A Chi-square test was used to determine the relationship between the categorical variables. Uni/Multi-variable linear regression analysis was used to quantify the associations between MetS and HIV by the independent variables.</p><p><strong>Results: </strong>The incidence of MetS according to ATP III and Iranian criteria were 42 (32.3%) and 45 (34.6%), which was higher in older patients (p=0.001) and those with more duration since HIV diagnosis (p=0.02). Around 33.1% and 16.1% were overweight and obese, respectively. Among the components of MetS, the highest prevalence (50.8%) was related to low HDL, and the lowest was related to fasting blood sugar (21.5%). The average body fat mass, protein mass, Soft lean mass, and percentage body fat were 18.54 ± 9.46 kg, 10.91 ± 2.17 kg, 51.31 ± 9.61 kg, and 24.86±10.25% that were higher in MetS group (p<0.05).</p><p><strong>Conclusion: </strong>Our study points out the high prevalence of MetS in an Iranian population living with HIV, especially those suffering from the underlying disease for a longer time. Conducting multi-centric studies with larger sample sizes is needed to confirm our results and determine the most effective measures.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"77-84"},"PeriodicalIF":1.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the Effectiveness of Mindfulness-based Cognitive Therapy and Silva-based Relaxation Therapy on Psychological Capital, Social Anxiety, and CD4+ Count in People Living with HIV in Iran. 正念认知疗法和席尔瓦放松疗法对伊朗HIV感染者心理资本、社交焦虑和CD4+计数的效果比较
IF 0.8 4区 医学 Q4 IMMUNOLOGY Pub Date : 2025-01-01 DOI: 10.2174/011570162X321129241129040921
Pegah Mirzapour, Abbas Boosiraz, Mohammad Mahdi Roozbahani, Maryam S Fakhri B, SeyedAhmad SeyedAlinaghi

Background/ Objective: Due to the impact of human immunodeficiency virus (HIV) infection on personal and social life, people living with HIV (PLWH) are faced with several challenges and issues. Therefore, PLWH requires psychological interventions. The study aims were to create a suitable platform for psychological structures that empower them to address their issues effectively. In this regard, we evaluated the effect of Mindfulness-based Cognitive Therapy (MBCT) and Silva-based Relaxation Therapy (SBRT) on Psychological Capital (PsyCap), Social Anxiety (SA), and CD4 count in PLWH.

Methods: This study employed an intervention-based semi-experimental design. The population consisted of 90 individuals infected with HIV. Participants were divided into two experimental groups receiving MBCT and SBRT, respectively, and one control group, selected randomly. Before and after the intervention, questionnaires and CD4+ tests were administered to the participants. Only two experimental groups received the intervention, while the control group received no training. The appropriate training for each group was conducted twice a week over eight sessions and each session lasted 90 minutes. In the intervention groups, all the people participated in all the group training sessions. No intervention was performed for the participants of the control group, and they only completed the questionnaires in the same period as the intervention groups. "Mindfulness-Based Cognitive Therapy" and "Mind Control" books were used for the implementation of MBCT and SBRT, respectively.

Results: It was revealed that a number of male participants constituted the majority with 58 (64.4%) compared to females. Regarding the means of transmission, sexual contact was the most common with 62 (68.8%) compared to other routes. The mean age of the participants was 40.5 ± 10.8 years. For the SBRT group, the mean CD4+ count was higher, with 599.5 ± 290.9 for pre-test and 563.2 ± 366.7 for post-test assessments, compared to other groups. After performing the linear regression analysis, it was found that the variables had no effect on the main outcome, which is CD4 count after the intervention (p-value= 0.27). For the MBCT group, the CD4+ count variable had a p-value = 0.10 (pretest: 447.2 ± 19.5, posttest: 411.9 ± 235.9), for the SBRT group, the CD4+ count variable had a p-value = 0.05 (pretest: 599.5 ± 290.9, posttest: 549 ± 259.9), and the control group, the CD4+ count variable had a p-value = 0.5 (pretest: 445 ± 222.7, posttest: 563.2 ± 366.7).

Conclusion: MBCT and SBRT may enhance the mental well-being of PLWH. Therefore, following the interventions, the mean level of SA decreased, and PsyCap increased. Thus, strategies to improve psychological support interventions may have a significant impact on improving the health status of individuals living with HIV, including indicators of SA and PsyCap.

背景/目的:由于人类免疫缺陷病毒(HIV)感染对个人和社会生活的影响,HIV感染者(PLWH)面临着许多挑战和问题。因此,PLWH需要心理干预。这项研究的目的是为心理结构创造一个合适的平台,使他们能够有效地解决他们的问题。在这方面,我们评估了基于正念的认知疗法(MBCT)和基于席尔瓦的放松疗法(SBRT)对PLWH心理资本(PsyCap)、社交焦虑(SA)和CD4计数的影响。方法:采用以干预为基础的半实验设计。人口中有90人感染了艾滋病毒。将参与者随机分为两个实验组,分别接受MBCT和SBRT治疗,另设一个对照组。在干预前后,对参与者进行问卷调查和CD4+测试。只有两个实验组接受了干预,而对照组没有接受任何训练。每组的适当训练每周进行两次,共8次,每次训练持续90分钟。在干预组中,所有的人都参加了所有的小组训练课程。对照组不进行干预,只与干预组同期完成问卷。“正念认知疗法”和“精神控制”书籍分别用于MBCT和SBRT的实施。结果:与女性相比,男性参与者占多数,有58人(64.4%)。在传播途径方面,性接触最为常见,有62例(68.8%),其他途径次之。参与者的平均年龄为40.5±10.8岁。与其他组相比,SBRT组的平均CD4+计数更高,测试前为599.5±290.9,测试后为563.2±366.7。经线性回归分析发现,各变量对干预后CD4计数这一主要转归无影响(p值= 0.27)。MBCT组CD4+计数变量的p值= 0.10(前测:447.2±19.5,后测:411.9±235.9),SBRT组CD4+计数变量的p值= 0.05(前测:599.5±290.9,后测:549±259.9),对照组CD4+计数变量的p值= 0.5(前测:445±222.7,后测:563.2±366.7)。结论:MBCT和SBRT可提高PLWH患者的心理幸福感。因此,在干预后,SA的平均水平下降,而PsyCap增加。因此,改善心理支持干预措施的策略可能对改善艾滋病毒感染者的健康状况产生重大影响,包括SA和PsyCap指标。
{"title":"Comparison of the Effectiveness of Mindfulness-based Cognitive Therapy and Silva-based Relaxation Therapy on Psychological Capital, Social Anxiety, and CD4<sup>+</sup> Count in People Living with HIV in Iran.","authors":"Pegah Mirzapour, Abbas Boosiraz, Mohammad Mahdi Roozbahani, Maryam S Fakhri B, SeyedAhmad SeyedAlinaghi","doi":"10.2174/011570162X321129241129040921","DOIUrl":"10.2174/011570162X321129241129040921","url":null,"abstract":"<p><p>Background/ Objective: Due to the impact of human immunodeficiency virus (HIV) infection on personal and social life, people living with HIV (PLWH) are faced with several challenges and issues. Therefore, PLWH requires psychological interventions. The study aims were to create a suitable platform for psychological structures that empower them to address their issues effectively. In this regard, we evaluated the effect of Mindfulness-based Cognitive Therapy (MBCT) and Silva-based Relaxation Therapy (SBRT) on Psychological Capital (PsyCap), Social Anxiety (SA), and CD4 count in PLWH.</p><p><strong>Methods: </strong>This study employed an intervention-based semi-experimental design. The population consisted of 90 individuals infected with HIV. Participants were divided into two experimental groups receiving MBCT and SBRT, respectively, and one control group, selected randomly. Before and after the intervention, questionnaires and CD4+ tests were administered to the participants. Only two experimental groups received the intervention, while the control group received no training. The appropriate training for each group was conducted twice a week over eight sessions and each session lasted 90 minutes. In the intervention groups, all the people participated in all the group training sessions. No intervention was performed for the participants of the control group, and they only completed the questionnaires in the same period as the intervention groups. \"Mindfulness-Based Cognitive Therapy\" and \"Mind Control\" books were used for the implementation of MBCT and SBRT, respectively.</p><p><strong>Results: </strong>It was revealed that a number of male participants constituted the majority with 58 (64.4%) compared to females. Regarding the means of transmission, sexual contact was the most common with 62 (68.8%) compared to other routes. The mean age of the participants was 40.5 ± 10.8 years. For the SBRT group, the mean CD4+ count was higher, with 599.5 ± 290.9 for pre-test and 563.2 ± 366.7 for post-test assessments, compared to other groups. After performing the linear regression analysis, it was found that the variables had no effect on the main outcome, which is CD4 count after the intervention (p-value= 0.27). For the MBCT group, the CD4+ count variable had a p-value = 0.10 (pretest: 447.2 ± 19.5, posttest: 411.9 ± 235.9), for the SBRT group, the CD4+ count variable had a p-value = 0.05 (pretest: 599.5 ± 290.9, posttest: 549 ± 259.9), and the control group, the CD4+ count variable had a p-value = 0.5 (pretest: 445 ± 222.7, posttest: 563.2 ± 366.7).</p><p><strong>Conclusion: </strong>MBCT and SBRT may enhance the mental well-being of PLWH. Therefore, following the interventions, the mean level of SA decreased, and PsyCap increased. Thus, strategies to improve psychological support interventions may have a significant impact on improving the health status of individuals living with HIV, including indicators of SA and PsyCap.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"35-43"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Latent Tuberculosis Screening and Active Tuberculosis Disease Development in People Living with HIV: A Multicenter Retrospective Cohort Study in Turkiye. 潜伏性肺结核筛查和活动性肺结核在艾滋病毒携带者中的发展:土耳其的一项多中心回顾性队列研究
IF 0.8 4区 医学 Q4 IMMUNOLOGY Pub Date : 2025-01-01 DOI: 10.2174/011570162X349937250206073759
Ferit Kuscu, Figen Yildirim, Damla Erturk, Mehmet Cabalak, Suheyla Komur, Ayse Seza Inal, Behice Kurtaran, Yesim Tasova, Aslihan Candevir

Background: About 10% of individuals with latent tuberculosis infection (LTBI) develop tuberculosis (TB) disease during their lifetime. People living with HIV (PLWH) have a significantly higher risk of developing tuberculosis disease from latent tuberculosis infection (LTBI) compared to those without HIV. Many HIV treatment guidelines recommend screening and treating for LTBI.

Objective: This study aimed to investigate the LTBI screening frequency of PLWH and the rates of tuberculosis disease development during their follow-up.

Methods: A total of 483 PLWH were admitted to 3 research hospitals between January 2005 and April 2020. Patients who were 18 years and older, who did not have active TB disease, and who were followed up regularly were included in the study. Demographic characteristics and laboratory results of the patients, and tuberculin skin test (TST) and/or interferon gamma releasing assay (IGRA) results were recorded. Whether TB developed during the follow-up of the patients or not was recorded.

Results: A total of 482 PLWH were enrolled in the study, and 429 (89%) of them were male. The mean age of the patients was 37±13 years. The patients were followed for an average of 27.5 months (2-180 months). The mean CD4 count was 381±246/mm3 at the time of diagnosis. A total of 331 patients (68.7%) were screened for latent infection, and 62 (18.7%) of them were diagnosed with LTBI. During the follow-up of the patients, TB disease did not develop in anyone who was not screened for LTBI, while TB disease developed in 4 people who were screened. The mean age of PLWH who developed tuberculosis disease was 54±10 years, while those who did not develop it was 37±13 years, and the difference was statistically significant (p=0.009).

Conclusion: Screening for LTBI in PLWH and treating it when positive are recommended in the EACS guidelines. However, some local HIV guidelines recommend latent TB treatment according to ethnicity, CD4 count, and antiretroviral therapy use. Although the mean follow-up period was short, it was found that there was no difference in the development of TB disease in LTBIpositive and negative individuals in our study. For countries that are not on the list of high-burden countries for TB, it may be an option to give latent TB treatment only to selected patients who have lower CD4 counts.

背景:大约10%的潜伏性结核感染(LTBI)患者在其一生中发展为结核(TB)疾病。与未感染艾滋病毒的人相比,艾滋病毒感染者(PLWH)从潜伏结核感染(LTBI)发展为结核病的风险明显更高。许多HIV治疗指南建议筛查和治疗LTBI。目的:本研究旨在探讨PLWH随访期间LTBI筛查频率及肺结核发病率。方法:2005年1月至2020年4月,在3家研究医院共收治483例PLWH。18岁及以上的患者,没有活动性结核病,并定期随访,包括在研究中。记录患者的人口学特征和实验室结果,以及结核菌素皮肤试验(TST)和/或干扰素释放试验(IGRA)结果。记录患者随访期间是否发生结核病。结果:共纳入482例PLWH,其中男性429例(89%)。患者平均年龄37±13岁。平均随访27.5个月(2 ~ 180个月)。诊断时平均CD4计数为381±246/mm3。共筛查潜伏感染331例(68.7%),其中62例(18.7%)诊断为LTBI。在对患者的随访期间,未进行LTBI筛查的患者均未发生结核病,而接受筛查的患者中有4人发生了结核病。发生结核病的PLWH平均年龄为54±10岁,未发生结核病的PLWH平均年龄为37±13岁,差异有统计学意义(p=0.009)。结论:EACS指南建议在PLWH中筛查LTBI,阳性时进行治疗。然而,一些地方艾滋病毒指南建议根据种族、CD4计数和抗逆转录病毒治疗的使用来治疗潜伏性结核病。虽然平均随访时间较短,但在我们的研究中发现ltbi阳性和阴性个体在结核病的发展方面没有差异。对于不在结核病高负担国家名单上的国家,可以选择仅对CD4计数较低的选定患者提供潜伏性结核病治疗。
{"title":"Latent Tuberculosis Screening and Active Tuberculosis Disease Development in People Living with HIV: A Multicenter Retrospective Cohort Study in Turkiye.","authors":"Ferit Kuscu, Figen Yildirim, Damla Erturk, Mehmet Cabalak, Suheyla Komur, Ayse Seza Inal, Behice Kurtaran, Yesim Tasova, Aslihan Candevir","doi":"10.2174/011570162X349937250206073759","DOIUrl":"10.2174/011570162X349937250206073759","url":null,"abstract":"<p><strong>Background: </strong>About 10% of individuals with latent tuberculosis infection (LTBI) develop tuberculosis (TB) disease during their lifetime. People living with HIV (PLWH) have a significantly higher risk of developing tuberculosis disease from latent tuberculosis infection (LTBI) compared to those without HIV. Many HIV treatment guidelines recommend screening and treating for LTBI.</p><p><strong>Objective: </strong>This study aimed to investigate the LTBI screening frequency of PLWH and the rates of tuberculosis disease development during their follow-up.</p><p><strong>Methods: </strong>A total of 483 PLWH were admitted to 3 research hospitals between January 2005 and April 2020. Patients who were 18 years and older, who did not have active TB disease, and who were followed up regularly were included in the study. Demographic characteristics and laboratory results of the patients, and tuberculin skin test (TST) and/or interferon gamma releasing assay (IGRA) results were recorded. Whether TB developed during the follow-up of the patients or not was recorded.</p><p><strong>Results: </strong>A total of 482 PLWH were enrolled in the study, and 429 (89%) of them were male. The mean age of the patients was 37±13 years. The patients were followed for an average of 27.5 months (2-180 months). The mean CD4 count was 381±246/mm3 at the time of diagnosis. A total of 331 patients (68.7%) were screened for latent infection, and 62 (18.7%) of them were diagnosed with LTBI. During the follow-up of the patients, TB disease did not develop in anyone who was not screened for LTBI, while TB disease developed in 4 people who were screened. The mean age of PLWH who developed tuberculosis disease was 54±10 years, while those who did not develop it was 37±13 years, and the difference was statistically significant (p=0.009).</p><p><strong>Conclusion: </strong>Screening for LTBI in PLWH and treating it when positive are recommended in the EACS guidelines. However, some local HIV guidelines recommend latent TB treatment according to ethnicity, CD4 count, and antiretroviral therapy use. Although the mean follow-up period was short, it was found that there was no difference in the development of TB disease in LTBIpositive and negative individuals in our study. For countries that are not on the list of high-burden countries for TB, it may be an option to give latent TB treatment only to selected patients who have lower CD4 counts.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"69-75"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Virological Failure And HIV-1 Drug Resistance in Indian Adults and Adolescents on Protease Inhibitor Based Second-line Antiretroviral Therapy: A Five-year Follow-up Study. 基于蛋白酶抑制剂的二线抗逆转录病毒治疗在印度成人和青少年中的病毒学失败和HIV-1耐药性:一项为期五年的随访研究。
IF 1 4区 医学 Q4 IMMUNOLOGY Pub Date : 2025-01-01 DOI: 10.2174/011570162X344689250331081024
Sumit Arora, Kuldeep Ashta, Nishant Raman, Charu Mohan, N Kisenjang, Vikram Sharma, Anirudh Anilkumar
<p><strong>Introduction: </strong>In the changing HIV treatment landscape, the focus shifts to persons living with HIV (PLH) experiencing virological non-suppression on second-line antiretroviral therapy (ART). This includes understanding viral genetic profiles, antiretroviral susceptibility, and the effectiveness of protease inhibitors (PIs) amid evolving dolutegravir-based regimen recommendations.</p><p><strong>Methods: </strong>In this retrospective study, PLH with first-line ART failure transitioned to second-line ART (dual NRTI + ritonavir-boosted PI) between September 2015 and October 2018. Eligible patients were ≥ 13 years old, with ≥ 9 months on first-line ART, and confirmed adherence at firstline regimen failure. Conducted at a Northern Indian tertiary hospital, this 5 year follow-up examined virological outcomes and drug resistance. Follow-up included initial viral-load (VL) and CD4 testing at 6-months, subsequent VL testing every 6-12 months, clinical evaluations, and infection screenings. Data on demographics, treatment history, virological-failure (VF), and drug-resistance testing (DRT) (Viroseq HIV-1 genotyping-system) were analysed using Kaplan-Meier and Competing-risk analysis, with appropriate censoring and imputation for events like death, transfer-out, treatment discontinuation/ interruption, loss to follow-up (LTFU), or ART-regimen change.</p><p><strong>Results: </strong>219 PLH shifted to ritonavir-boosted PI based second-line ART after 68 (median) months (IQR: 68) of first-line ART exposure and were followed up for 57 (median) months (IQR: 48), totalling 11,548 person-months (PM) of follow-up. Virological outcomes were assessed in 201 PLH. VF cumulative-incidence (Kaplan-Meier-analysis) ranged from 6.9% at 36 months to 15.9% at 60 months. Imputation scenarios showed a potential range, with worst-case incidences of 16.2% at 36 months and 29.4% at 60 months. Cumulative-incidence function (CIF) of VF (Competing-risk-analysis) ranged from 6.5% at 36 months to 12.7% at 60 months. Among 171 PLH with complete VL data, VF incidence was 2.7 per 1000 PM (n=29), with 94.7% achieving nadir VL <1000 cp/mL. VF with PI-mutation (VF-M) analysis, including LTFU patients (n=183), showed CIF for VFM of 2.3% at 36 months and 4.9% at 60 months. DRT (n=23-sequences) revealed 17.4% lopinavir resistance, 34.8% atazanvir resistance, and darunavir (DRV) cross-resistance in three sequences. Overall, 26.1% had no significant drug-resistance mutations, 39.1% had NNRTI resistance, but no PI DRMs, and only 34.8% (of 23-PLH who underwent DRT) potentially required third-line ART.</p><p><strong>Conclusion: </strong>This 5-year longitudinal study highlights the resilience of PIs in second-line ART. The incidence of VF with PI-resistance was notably low, indicating the ongoing effectiveness of PIs in managing PLH on second-line ART and the possibility of recycling PIs in subsequent ART regimens for these patients. Cross-resistance to DRV patients highlights th
在不断变化的艾滋病毒治疗领域,重点转移到二线抗逆转录病毒治疗(ART)的病毒学无抑制的艾滋病毒感染者(PLH)身上。这包括了解病毒遗传谱、抗逆转录病毒易感性和蛋白酶抑制剂(pi)在不断发展的以多替格雷韦为基础的方案建议中的有效性。方法:在这项回顾性研究中,在2015年9月至2018年10月期间,一线ART失败的PLH过渡到二线ART(双NRTI +利托那韦增强PI)。符合条件的患者年龄≥13岁,接受一线抗逆转录病毒治疗≥9个月,并在一线方案失败时确认坚持治疗。在印度北部一家三级医院进行的这项为期5年的随访检查了病毒学结果和耐药性。随访包括6个月时的初始病毒载量(VL)和CD4检测,随后每6-12个月进行一次VL检测,临床评估和感染筛查。使用Kaplan-Meier和竞争风险分析分析人口统计学、治疗史、病毒学失败(VF)和耐药试验(DRT) (Viroseq HIV-1基因分型系统)的数据,并对死亡、转出、治疗终止/中断、随访缺失(LTFU)或art方案改变等事件进行适当的审查和归算。结果:219名PLH在一线ART暴露68(中位)个月(IQR: 68)后转而使用利托那韦增强的PI为基础的二线ART,随访57(中位)个月(IQR: 48),共随访11548人月(PM)。对201例PLH的病毒学结果进行了评估。VF累积发病率(kaplan - meier分析)从36个月时的6.9%到60个月时的15.9%不等。植入情景显示了潜在的范围,36个月时的最坏情况发生率为16.2%,60个月时为29.4%。VF(竞争风险分析)的累积发生率函数(CIF)从36个月时的6.5%到60个月时的12.7%不等。在171例具有完整VL数据的PLH中,VF发生率为2.7 / 1000 PM (n=29),其中94.7%达到最低点VL。结论:这项为期5年的纵向研究强调了二线ART中PIs的恢复能力。ppi耐药的VF发生率明显较低,表明PIs在二线抗逆转录病毒治疗中治疗PLH的持续有效性,以及在这些患者的后续抗逆转录病毒治疗方案中循环使用PIs的可能性。对DRV患者的交叉耐药性突出了加强治疗监测的必要性。
{"title":"Virological Failure And HIV-1 Drug Resistance in Indian Adults and Adolescents on Protease Inhibitor Based Second-line Antiretroviral Therapy: A Five-year Follow-up Study.","authors":"Sumit Arora, Kuldeep Ashta, Nishant Raman, Charu Mohan, N Kisenjang, Vikram Sharma, Anirudh Anilkumar","doi":"10.2174/011570162X344689250331081024","DOIUrl":"10.2174/011570162X344689250331081024","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;In the changing HIV treatment landscape, the focus shifts to persons living with HIV (PLH) experiencing virological non-suppression on second-line antiretroviral therapy (ART). This includes understanding viral genetic profiles, antiretroviral susceptibility, and the effectiveness of protease inhibitors (PIs) amid evolving dolutegravir-based regimen recommendations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this retrospective study, PLH with first-line ART failure transitioned to second-line ART (dual NRTI + ritonavir-boosted PI) between September 2015 and October 2018. Eligible patients were ≥ 13 years old, with ≥ 9 months on first-line ART, and confirmed adherence at firstline regimen failure. Conducted at a Northern Indian tertiary hospital, this 5 year follow-up examined virological outcomes and drug resistance. Follow-up included initial viral-load (VL) and CD4 testing at 6-months, subsequent VL testing every 6-12 months, clinical evaluations, and infection screenings. Data on demographics, treatment history, virological-failure (VF), and drug-resistance testing (DRT) (Viroseq HIV-1 genotyping-system) were analysed using Kaplan-Meier and Competing-risk analysis, with appropriate censoring and imputation for events like death, transfer-out, treatment discontinuation/ interruption, loss to follow-up (LTFU), or ART-regimen change.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;219 PLH shifted to ritonavir-boosted PI based second-line ART after 68 (median) months (IQR: 68) of first-line ART exposure and were followed up for 57 (median) months (IQR: 48), totalling 11,548 person-months (PM) of follow-up. Virological outcomes were assessed in 201 PLH. VF cumulative-incidence (Kaplan-Meier-analysis) ranged from 6.9% at 36 months to 15.9% at 60 months. Imputation scenarios showed a potential range, with worst-case incidences of 16.2% at 36 months and 29.4% at 60 months. Cumulative-incidence function (CIF) of VF (Competing-risk-analysis) ranged from 6.5% at 36 months to 12.7% at 60 months. Among 171 PLH with complete VL data, VF incidence was 2.7 per 1000 PM (n=29), with 94.7% achieving nadir VL &lt;1000 cp/mL. VF with PI-mutation (VF-M) analysis, including LTFU patients (n=183), showed CIF for VFM of 2.3% at 36 months and 4.9% at 60 months. DRT (n=23-sequences) revealed 17.4% lopinavir resistance, 34.8% atazanvir resistance, and darunavir (DRV) cross-resistance in three sequences. Overall, 26.1% had no significant drug-resistance mutations, 39.1% had NNRTI resistance, but no PI DRMs, and only 34.8% (of 23-PLH who underwent DRT) potentially required third-line ART.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This 5-year longitudinal study highlights the resilience of PIs in second-line ART. The incidence of VF with PI-resistance was notably low, indicating the ongoing effectiveness of PIs in managing PLH on second-line ART and the possibility of recycling PIs in subsequent ART regimens for these patients. Cross-resistance to DRV patients highlights th","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"133-144"},"PeriodicalIF":1.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Access to Language Interpretation Services at Health Care Facilities Providing Care to Adults Diagnosed with HIV in the United States, 2019. 2019年美国艾滋病毒感染者医疗机构的语言翻译服务可及性
IF 1 4区 医学 Q4 IMMUNOLOGY Pub Date : 2025-01-01 DOI: 10.2174/011570162X362664250527051957
Mabel Padilla, Linda Beer, Ruth E Luna-Gierke, Tracy Tie, Jen-Feng Lu, John Weiser

Introduction: People with limited English proficiency (LEP) experience barriers to healthcare access and optimal outcomes. Language interpretation services can facilitate clear communication- which is key to effective HIV care and treatment.

Methods: We analyzed weighted data from the 2019 cycle of the Medical Monitoring Project (MMP), a cross-sectional, complex sample survey of U.S. adults with diagnosed HIV, and data from the 2021 MMP Facility Survey, a survey of facilities providing care to 2019 MMP respondents. We estimated the percentage of people with HIV (PWH) with LEP who received care at facilities offering language interpretation services and facilities providing language interpretation services, overall and by selected characteristics.

Results: Overall, 89.9% of PWH with LEP received care at a facility with language interpretation services, and 83.6% of facilities provided language interpretation services. PWH with LEP who were unemployed were less likely than those who were employed to receive care at a facility with language interpretation services. Facilities that were Federally Qualified Health Centers, were not private practices, received Ryan White HIV/AIDS Program funding, and accepted public health care coverage were more likely to provide language interpretation services than facilities without these characteristics.

Discussion: Most PWH with LEP obtained HIV care at health care facilities providing language interpretation services, a positive finding as language is a common barrier to accessing care for people with LEP. Most facilities also provided language interpretation services, an important step towards ensuring meaningful access for people with LEP, as required by law.

Conclusion: Our findings demonstrate that most HIV care facilities are providing access to language services to PWH with LEP in the United States.

简介:英语水平有限(LEP)的人在获得医疗保健和获得最佳结果方面遇到障碍。语言翻译服务可以促进清晰的沟通,这是有效的艾滋病毒护理和治疗的关键。方法:我们分析了2019年医疗监测项目(MMP)周期的加权数据,这是一项对确诊为艾滋病毒的美国成年人进行的横断面复杂抽样调查,以及2021年MMP设施调查的数据,这是一项对2019年MMP受访者提供护理的设施的调查。我们估计了在提供语言翻译服务的机构和提供语言翻译服务的机构接受治疗的LEP艾滋病病毒感染者(PWH)的百分比,总体上和按选定的特征进行了评估。结果:总体而言,89.9%患有LEP的PWH在提供语言口译服务的机构接受护理,83.6%的机构提供语言口译服务。失业的LEP残疾人比有工作的残疾人更不可能在有语言翻译服务的机构接受护理。与没有这些特征的机构相比,获得联邦认证的医疗中心、非私人诊所、接受瑞安·怀特艾滋病毒/艾滋病项目资助、接受公共医疗保险的机构更有可能提供语言翻译服务。结论:我们的研究结果表明,在美国,大多数艾滋病毒护理机构都为患有LEP的PWH提供语言服务。
{"title":"Access to Language Interpretation Services at Health Care Facilities Providing Care to Adults Diagnosed with HIV in the United States, 2019.","authors":"Mabel Padilla, Linda Beer, Ruth E Luna-Gierke, Tracy Tie, Jen-Feng Lu, John Weiser","doi":"10.2174/011570162X362664250527051957","DOIUrl":"10.2174/011570162X362664250527051957","url":null,"abstract":"<p><strong>Introduction: </strong>People with limited English proficiency (LEP) experience barriers to healthcare access and optimal outcomes. Language interpretation services can facilitate clear communication- which is key to effective HIV care and treatment.</p><p><strong>Methods: </strong>We analyzed weighted data from the 2019 cycle of the Medical Monitoring Project (MMP), a cross-sectional, complex sample survey of U.S. adults with diagnosed HIV, and data from the 2021 MMP Facility Survey, a survey of facilities providing care to 2019 MMP respondents. We estimated the percentage of people with HIV (PWH) with LEP who received care at facilities offering language interpretation services and facilities providing language interpretation services, overall and by selected characteristics.</p><p><strong>Results: </strong>Overall, 89.9% of PWH with LEP received care at a facility with language interpretation services, and 83.6% of facilities provided language interpretation services. PWH with LEP who were unemployed were less likely than those who were employed to receive care at a facility with language interpretation services. Facilities that were Federally Qualified Health Centers, were not private practices, received Ryan White HIV/AIDS Program funding, and accepted public health care coverage were more likely to provide language interpretation services than facilities without these characteristics.</p><p><strong>Discussion: </strong>Most PWH with LEP obtained HIV care at health care facilities providing language interpretation services, a positive finding as language is a common barrier to accessing care for people with LEP. Most facilities also provided language interpretation services, an important step towards ensuring meaningful access for people with LEP, as required by law.</p><p><strong>Conclusion: </strong>Our findings demonstrate that most HIV care facilities are providing access to language services to PWH with LEP in the United States.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"203-213"},"PeriodicalIF":1.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12402997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of Total Lymphocyte Count, Human Immunodeficiency Virus Infection Status, and Tuberculosis Lesions on Chest X-ray: Can TLC Be an Alternative to CD4? 总淋巴细胞计数、人类免疫缺陷病毒感染状态和胸部x线结核病变的相关性:TLC可以替代CD4吗?
IF 1 4区 医学 Q4 IMMUNOLOGY Pub Date : 2025-01-01 DOI: 10.2174/011570162X330293250206093453
Vicky Septian Ariska, Netty Delvrita Lubis, Tambar Kembaren

Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis, often becomes a comorbidity in individuals infected with Human Immunodeficiency Virus (HIV), the cause of Acquired Immunodeficiency Syndrome (AIDS). HIV-positive individuals have a 30- fold higher risk of contracting TB compared to non-HIV individuals. Assessment of HIV-TB disease progression commonly relies on measuring CD4 cell counts. However, in areas with limited access, the World Health Organization (WHO) recommends using Total Lymphocyte Count (TLC) ≤ 1200 cells/μL as an alternative. Additionally, chest X-rays, a widely accessible radiological method, aid in diagnosing TB in HIV-positive patients, complementing TLC in assessing disease progression in limited facilities.

Objective: The objective of this study was to analyze the differences in the location and characteristics of TB lesions based on HIV status and TLC levels.

Methods: A case-control study was conducted at Adam Malik Central Hospital on pulmonary TB patients from December 2021 to December 2022, meeting inclusion criteria. Evaluation of TB lesion locations and characteristics was performed by two researchers, while HIV status and TLC data were extracted from medical records.

Results: The study involved 154 subjects, including 77 HIV-positive and 77 non-HIV individuals. The percentage of male participants was 81.8%, with a mean age of 43.4 ± 14.4 years. The significant differences in the characteristics and locations of lesions (cavities, miliary lesions, fibrosis, atelectasis, and upper and lower lung) were revealed in HIV-positive and HIV-negative patients. Similarly, significant differences in the characteristics and locations of lesions (cavities, miliary lesions, fibrosis, atelectasis, and upper and lower lung) were revealed in a patient with TLC ≤ 1200 and TLC > 1200.

Conclusion: The study highlights significant differences in the characteristics and locations of tuberculosis lesions about HIV status and total lymphocyte count levels among pulmonary TB patients. HIV-positive individuals exhibited distinct patterns of TB lesions compared to their HIV-negative counterparts, indicating the impact of HIV on TB disease progression. Furthermore, variations in lesion characteristics were also observed based on TLC levels, with notable differences between patients with TLC ≤ 1200 cells/μL and those with TLC > 1200 cells/μL. These findings underscore the importance of considering both HIV status and TLC in the assessment and management of TB in affected individuals. TLC can serve as an alternative to CD4 measurement in situations where access to CD4 testing is limited.

背景:结核(TB),由结核分枝杆菌引起,经常成为人类免疫缺陷病毒(HIV)感染个体的合并症,HIV是获得性免疫缺陷综合征(AIDS)的病因。艾滋病毒阳性个体感染结核病的风险比非艾滋病毒携带者高30倍。评估HIV-TB疾病进展通常依赖于测量CD4细胞计数。然而,在交通不便的地区,世界卫生组织(WHO)建议使用总淋巴细胞计数(TLC)≤1200个细胞/μL作为替代方法。此外,胸部x光是一种广泛使用的放射学方法,有助于诊断艾滋病毒阳性患者的结核病,在有限的设施中补充TLC来评估疾病进展。目的:本研究的目的是分析基于HIV状态和TLC水平的TB病变位置和特征的差异。方法:于2021年12月至2022年12月在亚当马利克中心医院对符合纳入标准的肺结核患者进行病例对照研究。两名研究人员对结核病病变部位和特征进行了评估,而HIV状态和TLC数据则从医疗记录中提取。结果:该研究涉及154名受试者,包括77名hiv阳性和77名非hiv个体。男性占81.8%,平均年龄43.4±14.4岁。hiv阳性和hiv阴性患者的病变特征和部位(空腔、军性病变、纤维化、肺不张、上下肺)有显著差异。同样,在TLC≤1200和TLC≤1200的患者中,病变(空腔、粟状病变、纤维化、肺不张、上下肺)的特征和位置也有显著差异。结论:本研究突出了肺结核患者的HIV状态和总淋巴细胞计数水平在结核病变的特征和部位上的显著差异。与艾滋病毒阴性个体相比,艾滋病毒阳性个体表现出不同的结核病病变模式,表明艾滋病毒对结核病进展的影响。此外,TLC水平在病变特征上也存在差异,TLC≤1200 cells/μL与TLC≤1200 cells/μL之间存在显著差异。这些发现强调了在受影响个体的结核病评估和管理中同时考虑艾滋病毒状况和TLC的重要性。在获得CD4检测有限的情况下,薄层色谱可作为CD4测量的替代方法。
{"title":"Correlation of Total Lymphocyte Count, Human Immunodeficiency Virus Infection Status, and Tuberculosis Lesions on Chest X-ray: Can TLC Be an Alternative to CD4?","authors":"Vicky Septian Ariska, Netty Delvrita Lubis, Tambar Kembaren","doi":"10.2174/011570162X330293250206093453","DOIUrl":"10.2174/011570162X330293250206093453","url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB), caused by Mycobacterium tuberculosis, often becomes a comorbidity in individuals infected with Human Immunodeficiency Virus (HIV), the cause of Acquired Immunodeficiency Syndrome (AIDS). HIV-positive individuals have a 30- fold higher risk of contracting TB compared to non-HIV individuals. Assessment of HIV-TB disease progression commonly relies on measuring CD4 cell counts. However, in areas with limited access, the World Health Organization (WHO) recommends using Total Lymphocyte Count (TLC) ≤ 1200 cells/μL as an alternative. Additionally, chest X-rays, a widely accessible radiological method, aid in diagnosing TB in HIV-positive patients, complementing TLC in assessing disease progression in limited facilities.</p><p><strong>Objective: </strong>The objective of this study was to analyze the differences in the location and characteristics of TB lesions based on HIV status and TLC levels.</p><p><strong>Methods: </strong>A case-control study was conducted at Adam Malik Central Hospital on pulmonary TB patients from December 2021 to December 2022, meeting inclusion criteria. Evaluation of TB lesion locations and characteristics was performed by two researchers, while HIV status and TLC data were extracted from medical records.</p><p><strong>Results: </strong>The study involved 154 subjects, including 77 HIV-positive and 77 non-HIV individuals. The percentage of male participants was 81.8%, with a mean age of 43.4 ± 14.4 years. The significant differences in the characteristics and locations of lesions (cavities, miliary lesions, fibrosis, atelectasis, and upper and lower lung) were revealed in HIV-positive and HIV-negative patients. Similarly, significant differences in the characteristics and locations of lesions (cavities, miliary lesions, fibrosis, atelectasis, and upper and lower lung) were revealed in a patient with TLC ≤ 1200 and TLC > 1200.</p><p><strong>Conclusion: </strong>The study highlights significant differences in the characteristics and locations of tuberculosis lesions about HIV status and total lymphocyte count levels among pulmonary TB patients. HIV-positive individuals exhibited distinct patterns of TB lesions compared to their HIV-negative counterparts, indicating the impact of HIV on TB disease progression. Furthermore, variations in lesion characteristics were also observed based on TLC levels, with notable differences between patients with TLC ≤ 1200 cells/μL and those with TLC > 1200 cells/μL. These findings underscore the importance of considering both HIV status and TLC in the assessment and management of TB in affected individuals. TLC can serve as an alternative to CD4 measurement in situations where access to CD4 testing is limited.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"99-106"},"PeriodicalIF":1.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in People Living with HIV-1. HIV-1感染者非酒精性脂肪肝患病率及相关因素
IF 1 4区 医学 Q4 IMMUNOLOGY Pub Date : 2025-01-01 DOI: 10.2174/011570162X340918250312040500
Fatma Nur Karatas, Caglayan Keklikkiran, Yusuf Yilmaz, Pinar Ay, Volkan Korten, Uluhan Sili

Background: Modern antiretroviral therapy (ART) prevents disease progression in people living with HIV. Due to the increasing age of people living with HIV, the detection and management of comorbidities has become more important.

Objective: In this study, we aimed to detect the prevalence of nonalcoholic fatty liver disease (NAFLD) and associated risk factors among people living with HIV followed up in our center.

Methods: This single-center, cross-sectional study included people living with HIV, on ART for ≥1 year and virologic suppression for ≥6 months, presenting for routine follow-up between October 1, 2021, and April 1, 2022. Participants with a concurrent etiology for hepatic steatosis were excluded. Transient elastography (TE) was performed. NAFLD was defined as a controlled attenuation parameter (CAP) ≥248 dB/m; significant fibrosis (≥F2) was defined as liver stiffness measurement ≥7.1 kPa.

Results: A total of 102 people living with HIV (84% men; median age, 39 years (IQR 33-52.5)) were enrolled. The treatment regimen of all participants included a nucleos(t)ide reverse transcriptase inhibitor and an integrase strand transfer inhibitor. TE analysis indicated NAFLD in 28 (27.5%) and fibrosis in 9 (8.8%; 6 with NAFLD) participants. In multivariable analysis, type two diabetes (OR:5.7 (95% CI 1.4-22.2), p=0.013), larger waist circumference (OR:1.1 (95% CI 1.03-1.16), p=0.007), higher alanine aminotransferase (OR:1.05 (95% CI 1.01-1.09), p=0.018), and higher thyroid stimulating hormone (OR:3.1 (95% CI 1.4-6.8), p=0.005) were independently associated with NAFLD.

Conclusion: We observed a significant prevalence of NAFLD among people living with HIV followed up in our center. The high prevalence of NAFLD in our sample mirrors that of the general population, likely due to rising rates of metabolic dysfunction. Our findings highlight the importance of timely screening and implementation of management strategies for NAFLD in this population.

背景:现代抗逆转录病毒治疗(ART)可预防艾滋病毒感染者的疾病进展。由于艾滋病毒感染者的年龄越来越大,合并症的检测和管理变得越来越重要。目的:在本研究中,我们旨在检测非酒精性脂肪性肝病(NAFLD)在我们中心随访的HIV感染者中的患病率及其相关危险因素。方法:这项单中心横断面研究纳入了接受抗逆转录病毒治疗≥1年且病毒学抑制≥6个月的艾滋病毒感染者,于2021年10月1日至2022年4月1日进行常规随访。同时患有肝脂肪变性的参与者被排除在外。进行瞬态弹性成像(TE)。NAFLD定义为可控衰减参数(CAP)≥248 dB/m;肝刚度≥7.1 kPa为显著纤维化(≥F2)。结果:共102例HIV感染者(84%为男性;中位年龄为39岁[IQR 33-52.5])。所有参与者的治疗方案包括核苷(t)逆转录酶抑制剂和整合酶链转移抑制剂。TE分析显示NAFLD 28例(27.5%),纤维化9例(8.8%);6名NAFLD参与者。在多变量分析中,2型糖尿病(OR:5.7 [95% CI 1.4-22.2], p=0.013)、较大腰围(OR:1.1 [95% CI 1.03-1.16], p=0.007)、较高的丙氨酸转氨酶(OR:1.05 [95% CI 1.01-1.09], p=0.018)和较高的促甲状腺激素(OR:3.1 [95% CI 1.4-6.8], p=0.005)与NAFLD独立相关。结论:我们观察到在我们中心随访的HIV感染者中NAFLD的显著流行。我们样本中NAFLD的高患病率反映了一般人群的高患病率,可能是由于代谢功能障碍的发生率上升。我们的发现强调了在这一人群中及时筛查和实施NAFLD管理策略的重要性。
{"title":"Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in People Living with HIV-1.","authors":"Fatma Nur Karatas, Caglayan Keklikkiran, Yusuf Yilmaz, Pinar Ay, Volkan Korten, Uluhan Sili","doi":"10.2174/011570162X340918250312040500","DOIUrl":"10.2174/011570162X340918250312040500","url":null,"abstract":"<p><strong>Background: </strong>Modern antiretroviral therapy (ART) prevents disease progression in people living with HIV. Due to the increasing age of people living with HIV, the detection and management of comorbidities has become more important.</p><p><strong>Objective: </strong>In this study, we aimed to detect the prevalence of nonalcoholic fatty liver disease (NAFLD) and associated risk factors among people living with HIV followed up in our center.</p><p><strong>Methods: </strong>This single-center, cross-sectional study included people living with HIV, on ART for ≥1 year and virologic suppression for ≥6 months, presenting for routine follow-up between October 1, 2021, and April 1, 2022. Participants with a concurrent etiology for hepatic steatosis were excluded. Transient elastography (TE) was performed. NAFLD was defined as a controlled attenuation parameter (CAP) ≥248 dB/m; significant fibrosis (≥F2) was defined as liver stiffness measurement ≥7.1 kPa.</p><p><strong>Results: </strong>A total of 102 people living with HIV (84% men; median age, 39 years (IQR 33-52.5)) were enrolled. The treatment regimen of all participants included a nucleos(t)ide reverse transcriptase inhibitor and an integrase strand transfer inhibitor. TE analysis indicated NAFLD in 28 (27.5%) and fibrosis in 9 (8.8%; 6 with NAFLD) participants. In multivariable analysis, type two diabetes (OR:5.7 (95% CI 1.4-22.2), p=0.013), larger waist circumference (OR:1.1 (95% CI 1.03-1.16), p=0.007), higher alanine aminotransferase (OR:1.05 (95% CI 1.01-1.09), p=0.018), and higher thyroid stimulating hormone (OR:3.1 (95% CI 1.4-6.8), p=0.005) were independently associated with NAFLD.</p><p><strong>Conclusion: </strong>We observed a significant prevalence of NAFLD among people living with HIV followed up in our center. The high prevalence of NAFLD in our sample mirrors that of the general population, likely due to rising rates of metabolic dysfunction. Our findings highlight the importance of timely screening and implementation of management strategies for NAFLD in this population.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"121-132"},"PeriodicalIF":1.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Electrochemical Sensors in Enhancing HIV Detection. 电化学传感器在增强HIV检测中的作用。
IF 0.8 4区 医学 Q4 IMMUNOLOGY Pub Date : 2025-01-01 DOI: 10.2174/011570162X363311250206045837
Xingxing Li, Jiangwei Zhu, Li Fu

Human Immunodeficiency Virus (HIV) remains a significant global health challenge, necessitating rapid, sensitive, and accessible diagnostic tools. We examined recent advancements in electrochemical sensors for HIV gene detection, focusing on various sensing strategies, nanomaterial integration, and novel platform designs. Electrochemical sensors have demonstrated remarkable progress in HIV detection, offering high sensitivity and specificity. DNA/RNA-based sensors, aptamer approaches, and nanostructured platforms have detection limits as low as attomolar concentrations. Innovative signal amplification techniques, such as branched DNA amplification and toehold strand displacement reactions, have further enhanced sensitivity. Multiplexed detection systems enable simultaneous quantification of multiple HIV targets and related biomarkers. Integration of microfluidic technologies has improved sample processing and detection efficiency. Paper-based sensors show promise for low-cost, disposable testing platforms suitable for resource-limited settings. While challenges remain in terms of selectivity in complex biological samples and point-of-care applicability, electrochemical sensors hold great potential for revolutionizing HIV diagnostics. Future developments in recognition elements, artificial intelligence integration, and combined sensing modalities are expected to address current limitations and expand the capabilities of these sensors, ultimately contributing to improved HIV management and epidemic control strategies.

人类免疫缺陷病毒(HIV)仍然是一个重大的全球健康挑战,需要快速、敏感和可获得的诊断工具。我们研究了用于HIV基因检测的电化学传感器的最新进展,重点关注各种传感策略、纳米材料集成和新型平台设计。电化学传感器具有较高的灵敏度和特异性,在HIV检测方面取得了显著进展。基于DNA/ rna的传感器、适体方法和纳米结构平台的检测限低至原子摩尔浓度。创新的信号扩增技术,如支链DNA扩增和支点链位移反应,进一步提高了灵敏度。多路检测系统能够同时量化多个HIV靶标和相关生物标志物。微流控技术的集成提高了样品处理和检测效率。基于纸张的传感器有望成为低成本、一次性的测试平台,适用于资源有限的环境。虽然在复杂生物样品的选择性和护理点适用性方面仍然存在挑战,但电化学传感器在彻底改变艾滋病毒诊断方面具有巨大潜力。未来在识别要素、人工智能集成和综合传感方式方面的发展预计将解决当前的限制并扩大这些传感器的能力,最终有助于改进艾滋病毒管理和流行病控制战略。
{"title":"The Role of Electrochemical Sensors in Enhancing HIV Detection.","authors":"Xingxing Li, Jiangwei Zhu, Li Fu","doi":"10.2174/011570162X363311250206045837","DOIUrl":"10.2174/011570162X363311250206045837","url":null,"abstract":"<p><p>Human Immunodeficiency Virus (HIV) remains a significant global health challenge, necessitating rapid, sensitive, and accessible diagnostic tools. We examined recent advancements in electrochemical sensors for HIV gene detection, focusing on various sensing strategies, nanomaterial integration, and novel platform designs. Electrochemical sensors have demonstrated remarkable progress in HIV detection, offering high sensitivity and specificity. DNA/RNA-based sensors, aptamer approaches, and nanostructured platforms have detection limits as low as attomolar concentrations. Innovative signal amplification techniques, such as branched DNA amplification and toehold strand displacement reactions, have further enhanced sensitivity. Multiplexed detection systems enable simultaneous quantification of multiple HIV targets and related biomarkers. Integration of microfluidic technologies has improved sample processing and detection efficiency. Paper-based sensors show promise for low-cost, disposable testing platforms suitable for resource-limited settings. While challenges remain in terms of selectivity in complex biological samples and point-of-care applicability, electrochemical sensors hold great potential for revolutionizing HIV diagnostics. Future developments in recognition elements, artificial intelligence integration, and combined sensing modalities are expected to address current limitations and expand the capabilities of these sensors, ultimately contributing to improved HIV management and epidemic control strategies.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"2-13"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of a Novel HIV-1 Recombinant Form Comprising CRF01_AE and Subtype C in Hebei Province, China. 一种包含CRF01_AE和C亚型的新型HIV-1重组形式在河北省的鉴定
IF 0.8 4区 医学 Q4 IMMUNOLOGY Pub Date : 2025-01-01 DOI: 10.2174/011570162X369438250131065639
Yapeng Guan, Jun Wang, Xinli Lu

Background: Circulating recombinant form (CRF) 01_AE and subtype C are two HIV-1 subtypes. In recent years, novel HIV-1 recombinant forms have become more and more prevalent in China; however, new HIV-1 CRF01_AE/C recombinant forms are less prevalent nationwide.

Objective: Our study aimed to investigate new recombinant forms between different HIV-1 subtypes and evaluate their transmission risk among men who have sex with men (MSM) in Hebei, China.

Methods: The near full-length genome (NFLG) of HIV-1 was identified using the analyses of the phylogenetic tree and gene breakpoints.

Results: In the present work, we have reported a novel HIV-1 recombinant form composed of CRF01_AE and subtype C. The NFLG of this CRF01_AE/C form contained eight gene subregions, with four subtype C gene segments inserted into the CRF01_AE backbone, consisting of I CRF01_AE (790-1,171 nt), Ⅱ subtype C (1,172-1,840 nt), Ⅲ CRF01_AE (1,841-5,089 nt), Ⅳ subtype C (5,090-5,666 nt), Ⅴ CRF01_AE (5,667-6,317 nt), Ⅵ subtype C (6,318-8,586 nt), Ⅶ CRF01_AE (8,587-9,246 nt), and Ⅷ subtype C (9,247-9,409 nt). This new recombinant form was identified as CRF140_0107.

Conclusion: The study suggested that it is important to monitor HIV-1 diversity to reduce HIV- 1 transmission in China.

背景:循环重组形式(CRF) 01_AE和C亚型是HIV-1的两种亚型。近年来,新型HIV-1重组病毒在中国越来越流行;然而,新的HIV-1 CRF01_AE/C重组形式在全国范围内不太普遍。目的:研究HIV-1不同亚型之间的新重组形式,并评估其在河北省男男性行为者(MSM)中的传播风险。方法:利用系统发育树和基因断点分析,鉴定HIV-1近全长基因组(NFLG)。结果:在目前的工作中,我们报道了一种由CRF01_AE和C亚型组成的新型HIV-1重组形式。该CRF01_AE/C形式的NFLG包含8个基因亚区,其中4个亚型C基因片段插入CRF01_AE骨干,包括I CRF01_AE (790-1,171 nt),Ⅱ亚型C (1,172-1,840 nt),ⅢCRF01_AE (1,841-5,089 nt),Ⅳ亚型C (5,090-5,666 nt),ⅤCRF01_AE (5,667-6,317 nt),Ⅵ亚型C (6,318-8,586 nt),ⅦCRF01_AE (8,587-9,246 nt)和Ⅷ亚型C (9,247-9,409 nt)。这种新的重组形式被命名为CRF140_0107。结论:监测HIV-1多样性对减少HIV-1在中国的传播具有重要意义。
{"title":"Identification of a Novel HIV-1 Recombinant Form Comprising CRF01_AE and Subtype C in Hebei Province, China.","authors":"Yapeng Guan, Jun Wang, Xinli Lu","doi":"10.2174/011570162X369438250131065639","DOIUrl":"10.2174/011570162X369438250131065639","url":null,"abstract":"<p><strong>Background: </strong>Circulating recombinant form (CRF) 01_AE and subtype C are two HIV-1 subtypes. In recent years, novel HIV-1 recombinant forms have become more and more prevalent in China; however, new HIV-1 CRF01_AE/C recombinant forms are less prevalent nationwide.</p><p><strong>Objective: </strong>Our study aimed to investigate new recombinant forms between different HIV-1 subtypes and evaluate their transmission risk among men who have sex with men (MSM) in Hebei, China.</p><p><strong>Methods: </strong>The near full-length genome (NFLG) of HIV-1 was identified using the analyses of the phylogenetic tree and gene breakpoints.</p><p><strong>Results: </strong>In the present work, we have reported a novel HIV-1 recombinant form composed of CRF01_AE and subtype C. The NFLG of this CRF01_AE/C form contained eight gene subregions, with four subtype C gene segments inserted into the CRF01_AE backbone, consisting of I CRF01_AE (790-1,171 nt), Ⅱ subtype C (1,172-1,840 nt), Ⅲ CRF01_AE (1,841-5,089 nt), Ⅳ subtype C (5,090-5,666 nt), Ⅴ CRF01_AE (5,667-6,317 nt), Ⅵ subtype C (6,318-8,586 nt), Ⅶ CRF01_AE (8,587-9,246 nt), and Ⅷ subtype C (9,247-9,409 nt). This new recombinant form was identified as CRF140_0107.</p><p><strong>Conclusion: </strong>The study suggested that it is important to monitor HIV-1 diversity to reduce HIV- 1 transmission in China.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"53-57"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunoinformatics Analysis of Potent Therapeutic Formulations for the Development of HIV-1 Nefmut-Carrying Engineered Exosomes. HIV-1携带nefmut的工程外泌体开发的有效治疗配方的免疫信息学分析。
IF 1 4区 医学 Q4 IMMUNOLOGY Pub Date : 2025-01-01 DOI: 10.2174/011570162X361821250512115612
Parisa Moradi Pordanjani, Azam Bolhassani, Fatemeh Heidarnejad, Elnaz Agi

Background: The concept of designer exosomes involves developing engineered exosomes to overcome the limitations of natural exosomes in targeted drug delivery and vaccine development.

Methods: In this study, the multiepitope constructs were designed based on immunogenic regions of mutant Nef protein of Human Immunodeficiency Virus-1 (HIV-1 Nefmut) that were prone to high Post-Translational Modifications (PTMs), such as palmitoylation and myristoylation. These constructs with high scores in PTMs were selected for interactions with molecules involved in exosome biogenesis, anchoring of a protein in membranes, and enzymes involved in PTMs (e.g., the mutant enzyme ZDHHC21 p.T209S). Moreover, the selected multiepitope construct with the highest PTM score and stable linkage with these molecules was fused to the first exon of the HIV- 1 Tat protein as an antigen candidate, and to GFP as a tracking tool for evaluating their effects on the PTM scores and affinity binding with various molecules.

Results: Our data demonstrated that the multiepitope construct No.13 had better scores for incorporation into exosomes compared to the whole sequences of Nefmut and wild-type Nef protein (Nefwt). Furthermore, the linkage of Tat protein to construct No. 13 did not hinder its loading in exosomes compared to GFP, suggesting the use of this construct in vaccine development.

Conclusion: The multiepitope construct No.13 harboring potent Nefmut epitopes can be applied for linkage with other viral antigens, enhancing their delivery into exosomes for therapeutic applications.

背景:设计外泌体的概念涉及开发工程化的外泌体,以克服天然外泌体在靶向药物传递和疫苗开发中的局限性。方法:在本研究中,基于人类免疫缺陷病毒-1 (HIV-1 Nefmut)突变体Nef蛋白易发生高翻译后修饰(PTMs)的免疫原性区域,如棕榈酰化和肉豆肉酰化,设计了多表位结构。这些在PTMs中得分高的构建体被选择用于与参与外泌体生物发生的分子、膜上蛋白质的锚定以及参与PTMs的酶(例如,突变酶ZDHHC21 p.T209S)的相互作用。此外,选择的具有最高PTM评分和与这些分子稳定连接的多表位结构作为抗原候选融合到HIV-1 Tat蛋白的第一个外显子上,并作为跟踪工具与GFP融合,以评估它们对PTM评分的影响以及与各种分子的亲和力结合。结果:我们的数据表明,与Nefmut和野生型Nef蛋白(Nefwt)的全序列相比,多表位构建物No.13在外泌体的整合得分更高。此外,与GFP相比,Tat蛋白与13号结构的连接并不妨碍其在外泌体中的装载,这表明该结构可用于疫苗开发。结论:含有有效Nef - mut表位的多表位构建物No.13可用于与其他病毒抗原的连锁,促进其进入外泌体的治疗应用。
{"title":"Immunoinformatics Analysis of Potent Therapeutic Formulations for the Development of HIV-1 Nef<sup>mut</sup>-Carrying Engineered Exosomes.","authors":"Parisa Moradi Pordanjani, Azam Bolhassani, Fatemeh Heidarnejad, Elnaz Agi","doi":"10.2174/011570162X361821250512115612","DOIUrl":"10.2174/011570162X361821250512115612","url":null,"abstract":"<p><strong>Background: </strong>The concept of designer exosomes involves developing engineered exosomes to overcome the limitations of natural exosomes in targeted drug delivery and vaccine development.</p><p><strong>Methods: </strong>In this study, the multiepitope constructs were designed based on immunogenic regions of mutant Nef protein of Human Immunodeficiency Virus-1 (HIV-1 Nef<sup>mut</sup>) that were prone to high Post-Translational Modifications (PTMs), such as palmitoylation and myristoylation. These constructs with high scores in PTMs were selected for interactions with molecules involved in exosome biogenesis, anchoring of a protein in membranes, and enzymes involved in PTMs (e.g., the mutant enzyme ZDHHC21 p.T209S). Moreover, the selected multiepitope construct with the highest PTM score and stable linkage with these molecules was fused to the first exon of the HIV- 1 Tat protein as an antigen candidate, and to GFP as a tracking tool for evaluating their effects on the PTM scores and affinity binding with various molecules.</p><p><strong>Results: </strong>Our data demonstrated that the multiepitope construct No.13 had better scores for incorporation into exosomes compared to the whole sequences of Nef<sup>mut</sup> and wild-type Nef protein (Nef<sup>wt</sup>). Furthermore, the linkage of Tat protein to construct No. 13 did not hinder its loading in exosomes compared to GFP, suggesting the use of this construct in vaccine development.</p><p><strong>Conclusion: </strong>The multiepitope construct No.13 harboring potent Nef<sup>mut</sup> epitopes can be applied for linkage with other viral antigens, enhancing their delivery into exosomes for therapeutic applications.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"180-202"},"PeriodicalIF":1.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current HIV Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1